FY2026 · ended Apr 30, 2026 · Revenue $0 · Filed Jul 29, 2026
Pharmacyte Biotech, Inc. (PMCB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2026, which ended Apr 30, 2026, it reported revenue of $0 and a net loss of $19.4 million.
Revenue (TTM)
$0
Net income (TTM)
$-16.15M
-1334.7% vs year-ago TTM
Operating cash flow (TTM)
$-3.94M
+14.3% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-2.20
-178.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
10.74M
+58.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Apr 30, 2026 |
FY 2025 Apr 30, 2025 |
FY 2024 Apr 30, 2024 |
FY 2023 Apr 30, 2023 |
FY 2022 Apr 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$6.9M | -$4.4M | -$8.5M | -$6.5M | -$4.4M |
| Net income | -$19.4M | $30.7M | $333,763 | -$4.3M | -$4.2M |
| Diluted EPS | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 |
| Operating cash flow | -$5.2M | -$3.0M | -$2.2M | -$3.8M | -$4.1M |
| Total assets | $46.8M | $55.2M | $59.9M | $73.3M | $90.6M |
| Total liabilities | $11.8M | $3.3M | $20.4M | $586,581 | $704,370 |
| Stockholders' equity | $33.3M | $51.9M | $27.6M | $72.7M | $89.9M |
| Cash and investments | $18.9M | $15.5M | $50.2M | $68.0M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Auditor change
|
Oct 16, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 10-K | Annual report | Jul 29, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Apr 2, 2026 | Mar 30, 2026 |
| 10-Q | Quarterly report | Mar 17, 2026 | Jan 31, 2026 |
| ARS | Annual report to shareholders | Mar 9, 2026 | Apr 30, 2025 |
All 472 Pharmacyte Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.